updat model reflect potenti gener neulasta
contribut nice increas mylan
gain traction approv nice repriev constant pressur
establish credibl complex product inde possibl even includ
neulasta chang long term
achiev anoth approv complex product complement copaxon
clearanc neulasta concern immunogen issu
mylan/biocon formul obvious incorrect credit
capabl persist manag team approv credibl
manag even improv like provid even greater
enthusiasm potenti difficult formul product like advair restasi
inde possibl doubt grant nice repriev given
on-going global pressur competitor busi believ
neulasta could prove nice durabl describ ad opportun
model inflect dcf per share establish new price target
maintain long-term thesi
potenti financi implic approv would assum take
roughli neulasta sale includ onpro roughli
franchis factor anticip yet confirm price discount
well like share penetr given partial year
onpro share market could inde captur roughli
sale year although competit landscap remain unclear believ
coheru eventu secur approv could later year
novemb action date even increas competit given size
brand opportun product still nice solid contributor
extend period time competitor continu work formul
well believ complex product could leav rel
attract market coheru secur approv
implic multi-fold revenu come nice margin
despit undisclos profit share biocon longer-dur
normal gener despit eventu declin new entrant unlik
ever fulli collaps also reliev near-term earn pressur lastli
establish credibl inde secur difficult formul product
financi implic increas estim reflect roughli
neulasta contribut nice increas thereaft
accordingli neulasta includ dcf increas per share nonetheless given
move morn belief base busi grow remain
pleas see page report import disclosur
